Sugi Predict

Sugi Predict / Compounds / SCHEMBL4793372

SCHEMBL4793372

SCHEMBL4793372

O=[N+]([O-])c1ccccc1NF

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 5/20 0.60
▸ L3MBTL1 Q9Y468 4/20 0.60
▸ TDP1 Q9NUW8 2/20 0.60
▸ ALDH1A1 P00352 2/20 0.60
▸ CASP7 P55210 1/20 0.60
▸ MEN1 O00255 5/20 0.56
▸ KMT2A Q03164 5/20 0.56
▸ MAPT P10636 7/20 0.53
▸ GAA P10253 2/20 0.53
▸ PKM P14618 1/20 0.53
▸ KAT2B Q92831 2/20 0.51
▸ RAB9A P51151 4/20 0.50
▸ NPC1 O15118 3/20 0.50
▸ PDK1 Q15118 1/20 0.49
▸ PDK2 Q15119 1/20 0.49
▸ PDK3 Q15120 1/20 0.49
▸ PDK4 Q16654 1/20 0.49
▸ EPAS1 Q99814 1/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ KCNMA1 Q12791 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL397773 0.82 MAPK1 (0.77) MAPK1L3MBTL1TDP1ALDH1A1CASP7
SCHEMBL12205174 0.78 MAPK1 (0.60) MAPK1L3MBTL1TDP1ALDH1A1CASP7
SCHEMBL728448 0.78 MEN1 (0.61) MAPK1L3MBTL1TDP1ALDH1A1CASP7
SCHEMBL30110487 0.78 MAPK1 (0.60) MAPK1L3MBTL1TDP1ALDH1A1CASP7
SCHEMBL297021 0.78 MAPK1 (0.60) MAPK1L3MBTL1TDP1ALDH1A1CASP7
SCHEMBL856759 0.78 MAPK1 (0.60) MAPK1L3MBTL1TDP1ALDH1A1CASP7
SCHEMBL973213 0.78 MAPK1 (0.60) MAPK1L3MBTL1TDP1ALDH1A1CASP7
SCHEMBL950729 0.78 MAPK1 (0.60) MAPK1L3MBTL1TDP1ALDH1A1CASP7
SCHEMBL373368 0.78 MAPK1 (0.60) MAPK1L3MBTL1TDP1ALDH1A1CASP7
SCHEMBL355102 0.78 MAPK1 (0.60) MAPK1L3MBTL1TDP1ALDH1A1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110452152-A 1,3- dioxoisoindolin benzamide compound and application thereof INST MATERIA MEDICA CAMS 2019-11-15 — — CN claimed
CN-109071782-A Use of donor-acceptor polymers based on fluorobenzooxadiazoles in electronics and photonics 香港科技大学 2018-12-21 — — CN claimed
CN-108948011-A A kind of preparation method of the sandy star in pula 华南农业大学 2018-12-07 — — CN claimed
CN-105669520-B O-phenylenediamine class selectivity histon deacetylase (HDAC) inhibitor containing tryptophan basic framework and its preparation method and application 山东大学 2018-10-30 — — CN claimed
CN-108707087-A A kind of 4-（To trifluoromethyl benzyl）Fluoro- 1,2,4 triphenylamine derivatives of -3- and its pharmaceutical composition and purposes 河北医科大学 2018-10-26 — — CN claimed
CN-107935858-A The preparation method of 5 fluorine, 2 nitrophenol 利尔化学股份有限公司 2018-04-20 — — CN claimed
CN-105669520-A Tryptophan basic skeleton-containing o-phenylenediamine selective histone deacetylase inhibitor and its preparation method and use 山东大学 2016-06-15 — — CN claimed
CN-104407066-A Analysis method of retigabine related substances ANHUI WANBANG MEDICAL TECHNOLOGY CO LTD 2015-03-11 — — CN claimed
CN-116348114-A Thiobenzimidazole derivatives or pharmaceutically acceptable salts thereof and use thereof 高丽大学校产学协力团 2023-06-27 — — CN disclosed
CN-114787136-A Substituted benzimidazole carboxamides and their use in the treatment of medical disorders 比亚尔R&D投资股份公司 2022-07-22 — — CN disclosed
US-11078189-B2 Pharmaceutical compounds ReViral Limited (GB) 2021-08-03 — — US disclosed
CN-107935858-B Preparation method of 5-fluoro-2-nitrophenol 利尔化学股份有限公司 2020-09-08 — — CN disclosed
US-20200172515-A1 PHARMACEUTICAL COMPOUNDS SILICON VALLEY BANK 2020-06-04 — — US disclosed
CN-110511209-A It can be used as the indole carboxamides compound of kinase inhibitor BRISTOL MYERS SQUIBB CO 2019-11-29 — — CN disclosed
CN-1913884-A Substituted benzazoles and methods of their use as inhibitors of RAF kinase CHIRON CORP (US) 2007-02-14 — — CN disclosed
CN-1655779-A substituted indoles and their use as Raf kinase inhibitors CHIRON CORP (US) 2005-08-17 — — CN disclosed
EP-1379522-A1 DIHYDRO-BENZO(b)(1,4)DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I F. HOFFMANN-LA ROCHE AG (CH) 2004-01-14 — — EP disclosed
WO-2002083665-A1 DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I F. HOFFMANN-LA ROCHE AG (CH) 2002-10-24 — — WO disclosed
CN-1333770-A Novel Bicyclic Compounds BASLIER PHARMACEUTICAL AG (CH) 2002-01-30 — — CN disclosed
CN-1209744-A Vitronectin receptor antagonists SMITHKLINE BEECHAM CORP (US) 1999-03-03 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11078189-B2 Pharmaceutical compounds HRH4, CHRM5, CHRM1 MAPK1 2667/4885L3MBTL1 3530/4885TDP1 4605/4885
US-20200172515-A1 PHARMACEUTICAL COMPOUNDS HRH4, CHRM5, CHRM1 MAPK1 2667/4885L3MBTL1 3530/4885TDP1 4605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.